Nonprofit organizations receive a total of $4.6 million in grants from Edwards Lifesciences Fund

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.

Grants made outside of the grant cycle are expected to reach $2.8 million by the end of the year, which includes funding to the University of California, Irvine related to the development of The Edwards Lifesciences Center for Advanced Cardiovascular Technology. This will bring total grants to $4.6 million in 2009 and more than $14 million since the fund's inception in 2004.

"Recognizing that the economy has caused many challenges, our fund is awarding more grants for programs that provide basic needs such as food, shelter and clothing this year," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "I'm proud that during these tough times, we have been able to increase both the amount of funding and the number of organizations that receive grants from The Edwards Lifesciences Fund. Partnering with these worthy organizations enables us to leverage their reach to strengthen our global communities."

The company established The Edwards Lifesciences Fund to support advancements in knowledge and improvements in quality of life, focusing primarily upon cardiovascular disease and the communities where Edwards' employees live and work. The fund has made grants to programs such as basic needs support, cardiac medical missions in underserved regions, and cardiovascular disease education and screening. More information about the fund, including a complete list of organizations that received grants during the 2009 grant cycle, is available at www.edwards.com/edwardsfund.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New nasal spray form of bumetanide shows promise for heart failure treatment